Cambridge joins EU partners in ten-million-euro proteomics project
The University of Cambridge has joined European partners in a major study of proteins which will shed light on the role played by biological systems in health and disease.
This kind of international partnership is essential
- Kathryn Lilley
The European Union has awarded ten million euros to a consortium of 18 research groups in the field of mass spectrometry based proteomics research.
European Proteomics Initiative Consortium (EPIC-XS)
, funded as part of the Horizon 2020 Work programme, is coordinated by Albert Heck, professor of biomolecular mass spectrometry and proteomics at Utrecht University. The project began on 1 January 2019 and will run for four years.
Proteomics, the large-scale study of proteins and their role in living cells and organisms, is an important technology used to gain insight into the function of biological systems. Proteomics has been applied in many different types of studies. These include understanding how cells of the body respond to drug treatment and discovering new biomarkers in body fluids such as blood serum that can be used to detect disease but also monitor how patients respond to treatment.
Proteomics research requires state of the art technology, in-house technical know-how, sustainable and robust workflow practices, successful and correct data interpretation, and data management. The EPIC-XS initiative will support researchers by providing them with access to state of the art proteomics equipment, and allowing them to submit research proposals that make use of the proteomics technology offered by the project.
Reproduced courtesy of the University of Cambridge
The University of Cambridge is acknowledged as one of the world's leading higher education and research institutions. The University was instrumental in the formation of the Cambridge Network and its Vice- Chancellor, Professor Stephen Toope, is also the President of the Cambridge Network.
University of Cambridge directory information